Side effects of Avatrombopag

Avatrombopag(Avatrombopag) is a thrombopoietin (TPO) receptor agonist used to treat patients with chronic immune thrombocytopenia and patients with chronic liver disease. Avatrombopag was approved by the USFDA in20185 It was approved for marketing by the Nikkei China Food and Drug Administration on August 28, 2020.

In patients with chronic liver disease, the most common adverse reactions(≥ 3%)are fever, abdominal pain, nausea, headache, fatigue and peripheral edema. In patients with chronic immune thrombocytopenia, the most common adverse reactions (≥ 10%) are headache, fatigue, contusion, epistaxis, upper respiratory tract infection, arthralgia, gum bleeding, petechiae, and nasopharyngitis. Concurrent use with dual moderate or severe CYP2C9 and CYP3A4 inhibitors may increase the AUC of avacizumab, which may increase the risk of Spodoptera litura poisoning. Reduce the starting dose of DOPTELET when used concomitantly with moderate or severe dual inhibitors of CYP2C9 and CYP3A4.

For patients starting on moderate or severe CYP2C9 and CYP3A4 dual inhibitors, monitor platelet counts and adjust DOPTELET dosage as needed while taking DOPTELET.

Avatrombopag has been launched in Laos and Bangladesh and has government approval. The retail price of Lucius Pharmaceutical Factory in Laos20mg28 tablets is about 600 yuan. Laos United Pharmaceutical Factory retail price20mg30tablets700About 1 yuan. The retail price of Bangladesh Ziska Pharmaceutical Factory is about 20mg 30 tablets1000yuan. The retail price of Bangladesh Yaopin International Pharmaceutical Factory is around 950 yuan for 20 mg 28 tablets. If you want to get more high-quality information, you can contact Yaode, and Yaode will do its best to help you learn more about high-quality overseas drugs.